Qurient Co., Ltd. (115180)
KRX SM KRX SM Primary Summary
Qurient Co., Ltd. (115180) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Qurient Co., Ltd. ever had a stock split?
Qurient Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Ki-Yean Nam CEO | KRX SM Exchange | - ISIN |
| South Korea Country | 31 Employees | - Last Dividend | 18 Dec 2023 Last Split | - IPO Date |
Overview
Qurient Co., Ltd. is a biotech entity actively engaged in the discovery and development of innovative drugs aimed at satisfying the unexplored medical needs worldwide. Initially founded as Quro Science Inc., the company underwent a rebranding in October 2011 to its current identity. Since its establishment in 2008 and being based in Seongnam-si, South Korea, Qurient has positioned itself both on the domestic and international stages of the biotech industry. The company's strategic focus on advancing its drug development pipeline showcases its commitment to addressing critical health challenges through scientific innovation.
Products and Services
The therapeutic pipeline of Qurient Co., Ltd. is characterized by a range of promising drug candidates in various stages of clinical development, each targeting a distinct unmet medical need:
- Q301 - As a topical 5LO inhibitor, Q301 is currently under investigation in a Phase II clinical trial. Its development is aimed at providing a new treatment option for patients suffering from atopic dermatitis, a widespread inflammatory skin condition that causes discomfort and itching.
- Telacebec (Q203) - Positioned as a Cyt bc1 Inhibitor, Telacebec is advancing through Phase II clinical trials to tackle Mycobacterial Infections including tuberculosis and non-TBM (tuberculous mycobacterial) infections. Its mechanism offers a novel approach in combating these persistent bacterial diseases.
- Adrixetinib (Q702) - This compound, acting as an Axl/Mer/CSF1R Inhibitor, has completed Phase I trials, aspiring to treat solid tumors. Adrixetinib's triple-action inhibition pathway holds potential for a breakthrough in the management of various cancer types, highlighting Qurient's dedication to oncology.
- Q901 - Being a selective CDK7 inhibitor, Q901 is in the early phase of development (Phase I) focusing on the treatment of solid tumors. The targeted nature of this inhibitor could lead to more effective and less toxic cancer therapies, signifying Qurient's innovative approach to drug development in oncology.
